Pancreatic in Biological Technology

GenVec Reports Second Quarter 2009 Financial Results

... data from our pivotal trial in locally-advanced pancreatic cancer early next year." Second Quarter ... Chemoradiation in Patients with Locally Advanced pancreatic Cancer: Interim Analysis of Overall Survival," ... pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently ...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

... of both our Phase 3 clinical trial of RG1068 for pancreatic imaging, and our Phase 2b clinical trial of ... to receive pivotal data from both our Phase 3 pancreatic imaging and Phase 2b bipolar depression studies ... imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. ...

EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours

... EndoHPB device for the palliation of biliary and pancreatic tumours. London ... EndoHPB device for the palliation of biliary and pancreatic tumours. The Habib™ EndoHPB is an ... is also Chair of Surgery and Head of Liver and pancreatic Surgery at Imperial College London and ...

The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding

... the nation's largest private supporter of pancreatic cancer research, today announced its first round ... work of The Genome Project, which decoded pancreatic cancer's complete genetic blueprint, while others ... essential to our growing understanding of pancreatic cancer. If successful, this research will move ...

Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results

... of our Phase 3 clinical trial of RG1068 for pancreatic imaging, initiation of our Phase 2b clinical ... imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment ...

Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)

... endoscopic procedures for diagnosing and treating pancreatic and biliary disease," said Michael P. Phalen, ... of life for patients, as demonstrated by our new pancreatic indication for the SpyGlass System, as well as ... entire pancreatico-biliary system, including the pancreatic ducts. The SpyScope Catheter is used in ...

FDA Clears Boston Scientific's SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System

... for diagnostic and therapeutic procedures for pancreatic disease NATICK, Mass., May 28 ... system, enabling physicians to diagnose and treat pancreatic cancer or pre-cancerous tissues. According ... fourth-leading cause of cancer death in the U.S. pancreatic cancer is a "silent" disease, with patients often ...

Groundbreaking Research Begins for Pancreatic and Lung Cancers

... program to study the genetics and cell biology of pancreatic cancer. Tissue and serum samples from patients ... identifying specific, targeted therapies to treat pancreatic cancer. " The traditional treatment ... the current research is the first to focus on pancreatic cancer, accepted to be the most fatal of common ...

Repligen Reports Third Quarter Fiscal Year 2009 Financial Results

... of our Phase 3 clinical trial of RG1068 for pancreatic imaging, and initiation of our Phase 2b clinical ... imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment ...

Novel Diabetes Drug Discovery Has Potential to Reverse Disease

... the human REG3a gene responsible for regenerating pancreatic islets, a process also known as islet ... that HIP stimulates insulin secretion in human pancreatic ductal tissue devoid of islets. HIP was also ... of islet restoration as a therapeutic approach. pancreatic islets contain four primary cell types and are ...

REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

... of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, ... bioactivity in the treatment of metastatic pancreatic cancer. The present study confirms the overall ... survival and over-all survival time in pancreatic cancer patients that had previously failed ...

Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

... of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. ... from the U.S. FDA for three clinical indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma. ... to treat patients with Rexin-G for advanced pancreatic cancer in the United States (Int'l J Oncol 2006). ...

Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program

... gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall ... and commercialize Virulizin(R) for advanced pancreatic cancer and other therapy areas in North and ... types, including colon cancer, melanoma, and pancreatic cancer, with low toxicity. Lorus has patent ...

The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch

... Professor's fight against pancreatic cancer and underscores his call-to-action for ... nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million ... private foundation dedicated to supporting pancreatic cancer research, announced the debut of a new ...

ARIUS presents new findings for anti-cancer antibody programs at AACR

... CD44, has a new potential cancer indication for pancreatic cancer. The new findings show anti-tumor effects in an established BxPC3 human pancreatic cancer model (78.7% tumor growth inhibition at 2 ... AR40A746.2.3, induced apoptosis in BxPC-3 pancreatic cancer cell as a monotherapy. Moreover, apoptosis ...

Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)

... the agreement will be in advanced pancreatic cancer. Under the terms of the agreement, ... option not only for patients with advanced pancreatic cancer, one of the most difficult cancers to ... against a number of cancer indications including pancreatic cancer. Virulizin(R) has been granted orphan drug ...

Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project

... foundation dedicated exclusively to supporting pancreatic cancer research, will tomorrow hold a kick-off ... antibodies for promising biomarker targets for pancreatic cancer, the fourth leading cause of cancer deaths in the United States. The pancreatic Cancer Biomarker Development Project is a ...

Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice

... embryonic stem (hES) cells can be turned into pancreatic cells capable of producing insulin in mice. The ... cells capable of producing insulin and other pancreatic hormones. In this new work, Novocell has demonstrated that implantation of hES-derived pancreatic cells into mice results in the generation ...

Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial

... actively enrolling. Phase 2 Trial of TPI 287 for pancreatic Cancer Initiated Tapestry also initiated in the ... to explore the activity of TPI 287 in advanced pancreatic cancer. The trial is a multi-center, open-label, ... to 65 patients with advanced stage, unresectable pancreatic cancer, who have failed a prior ...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

... by 2016. The new Pharmacor report entitled pancreatic Cancer finds that Pharmexa's GV1001 and Cell ... deaths in the United States. As a result, the pancreatic cancer market carries extensive unmet medical ... "Experts argue that the development model for pancreatic therapies needs to be reviewed, that more effort ...

YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER

... patients with locally advanced or metastatic pancreatic cancer who will be treated with either ... that it will extend the European trial in pancreatic cancer into Canada by submitting the ... glioma, non-small-cell lung cancer and pancreatic cancer and YM expects that the range of ...

Response Genetics Reports Second Quarter 2007 Financial Results

... study to develop a diagnostic test kit for pancreatic cancer. The study will combine patient outcomes ... archival formalin-fixed paraffin-embedded (FFPE) pancreatic tissue samples. The results could potentially ... development of assays and diagnostic tests for pancreatic cancer. The study will be conducted in ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... at Harvard University . A world authority in developmental biology, pancreatic development, and metabolic disease, Dr. Melton recently published successful in-vivo reprogramming of exocrine pancreatic cells into insulin secreting cells without reversion to a pluripotent stem ...

Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

... b. Complete a randomised Phase II study with IV CP-4126 in pancreatic cancer c. Complete Phase I study for Oral CP-4126 in various ... controlled Phase II trial for Intravenous CP-4126, our second product, in pancreatic cancer. We aim to complete this trial and other ongoing clinical trials ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... in vitro in a number of cell lines, including breast cancer, lung cancer, pancreatic cancer, prostate cancer, and bladder cancer, and in several mouse ... in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to ...

Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial

... of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The ... www.oncolyticsbiotech.com Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit ...

Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers

... "We are excited about continuing the development of PAS in pancreatic and gastric cancers," said Lynda Sutton, COO of Cato Research and ... to develop PAS as a novel, cancer vaccine for the treatment of gastric and pancreatic cancers. Cancer Advances will announce a $50 million Series A financing ...

CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008

... Options for Patients with Lung, Prostate, Liver and pancreatic Cancer SUNNYVALE, Calif., Oct. 24 /PRNewswire-FirstCall/ -- ... saw an increase of 52 percent in patients during fiscal year 2008. -- pancreatic cancer -- There was a 15 percent increase in pancreatic cancer treatment ...

33rd ESMO Congress in Stockholm, 12-16 September 2008

... cancer Late breaking data: New drug substantially extends survival in pancreatic cancer (Embargoed until Tuesday, 16 September 2008, 10:00 CEST) A new ... produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, Prof. Matthias Lohr from the Karolinska Institute reports. ...

PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet

... pulmonary infection with Pseudomonas or other pathogenic bacteria, and pancreatic insufficiency. Patients were assessed in two 14-day treatment courses of ... lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a ...

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer

... the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned ... activity without toxicity in patients with progressive chemo-resistant pancreatic cancer. Once the overall safety record of repeated infusions of Rexin-G ...

Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

... efficacy in a broad spectrum of chemotherapy refractory cancers, including pancreatic cancer, breast cancer, colon cancer, squamous cell carcinoma of larynx, ... as a single therapeutic agent in treating chemotherapy refractory pancreatic cancer. Based on its exemplary record of safety and efficacy as an ...

EntreMed Announces 2008 Corporate and Clinical Program Priorities

... (NSCLC), hematological cancers, ovarian and endometrial cancer, and pancreatic cancer. Milestones for MKC-1 in 2008 include reporting results for the ... study (2Q08); and presentation of interim data for a Phase 2 study in pancreatic cancer (4Q08). -- ENMD-1198 is a potent, orally-active, antimitotic ...

BioVex Closes Second Round of Series E Financing

... of melanoma as well as to complete studies in head and neck cancer and pancreatic cancer. The financing will also fund the Company's second program, ... for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging ...

YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS

... cancer, adult and pediatric glioma, non-small-cell lung cancer and pancreatic cancer. YM expects that the range of indications will continue to broaden ... AG reported initiation of late-stage trials in adult glioma and pancreatic cancer. - YM reported positive preliminary results of a Phase I/II trial ...

Smart insulin nanostructures pass feasibility test, UT study reports

... system stabilized blood sugar levels in animal models with suppressed pancreatic functions for up to six hours, researchers reported. It is an inhalable ... diabetes, a condition that develops when the bodys immune system destroys pancreatic beta cells the only cells that make insulin. High blood sugar levels can ...

Sunesis Reports Financial Results for the Second Quarter 2009

... cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there were an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer ...

GenVec Expands Contract Supporting Malaria Vaccine Program

... novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal ...

NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region

... diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union. The ...

NewLink Genetics Corporation Closes $7.5 Million Financing

... Officer of NewLink Genetics Corporation. "The proceeds of this financing will allow us to both rapidly move our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our IDO inhibitor, D-1MT, into multiple Phase 2 studies." About NewLink Genetics ...